


**UChicago Grand Rounds Program: New Developments in the Management of Hematological Malignancies & Transplant January 23, 2013 Activity Eval.**

**1. Please identify yourself:**

		Response Percent	Response Count
MD/DO		100.0%	5
Nurse		0.0%	0
Fellow/Resident		0.0%	0
answered question			5
skipped question			0

**2. Prior to participating in this activity, please rate your ability to: (5=Completely, 1=Not at all)**

	5	4	3	2	1	Rating Average	Rating Count
Transplantation: Understand evolving indications for transplantation in non-Hodgkin's lymphomas & chronic lymphocytic leukemia.	80.0% (4)	0.0% (0)	20.0% (1)	0.0% (0)	0.0% (0)	4.60	5
Multiple Myeloma: Understand the evolving strategy of initial management of multiple myeloma; New developments & drugs for treatment of relapsed & refractory myeloma	80.0% (4)	0.0% (0)	20.0% (1)	0.0% (0)	0.0% (0)	4.60	5
Lymphoma: Understand the treatment approaches for newly diagnosed non-Hodgkin's lymphomas; New agents on the horizon for non-Hodgkin's lymphomas	80.0% (4)	0.0% (0)	20.0% (1)	0.0% (0)	0.0% (0)	4.60	5
Leukemia: Understand new insights from the myeloid neoplasms: How biology is revealing new opportunities for treatment; Progress in Lymphoid Malignancies: Hot off the press	80.0% (4)	20.0% (1)	0.0% (0)	0.0% (0)	0.0% (0)	4.80	5
answered question							5
skipped question							0

**3. After to participating in this activity, please rate your ability to: (5=Completely, 1=Not at all)**

	5	4	3	2	1	Rating Average	Rating Count
Transplantation: Understand Evolving indications for transplantation in non-Hodgkin's lymphomas & chronic lymphocytic leukemia.	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Multiple Myeloma: Understand the evolving strategy of initial management of multiple myeloma; New developments & drugs for treatment of relapsed & refractory myeloma	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Lymphoma: Understand the treatment approaches for newly diagnosed non-Hodgkin's lymphomas; New agents on the horizon for non-Hodgkin's lymphomas	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Leukemia: Understand new insights from the myeloid neoplasms: How biology is revealing new opportunities for treatment; Progress in Lymphoid Malignancies: Hot off the press	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
answered question							5
skipped question							0


#### 4. Did this activity:

	5	4	3	2	1	Rating Average	Rating Count
Address the competencies/attributes relevant to your specialty?	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Equip you with information to overcome barriers to treatment?	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Increase your competence, skills, and/or performance in providing improved patient care?	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
Present the material in a format appropriate to the topic?	<b>100.0% (5)</b>	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	5
answered question							5
skipped question							0



#### 5. After participating in this activity, will you make any changes in your practice? (Please explain).

	Response Count
	3
answered question	3
skipped question	2



**6. These are the barriers I face in my current practice setting that may impact patient outcomes:**

		Response Percent	Response Count
Lack of evidence-based guidelines;		0.0%	0
Lack of applicable guidelines for my current practice/patients;		0.0%	0
Lack of time;		0.0%	0
Organizational/institutional;		0.0%	0
<b>Insurance/financial;</b>		<b>100.0%</b>	<b>1</b>
Patient adherence/compliance;		0.0%	0
Treatment-related adverse events;		0.0%	0
Other (Please provide below).		0.0%	0
		.	0
answered question			1
skipped question			4

**7. How much of the content presented at this meeting was new to you?**

		Response Percent	Response Count
0-20%		0.0%	0
21-40%		25.0%	1
<b>41-60%</b>		<b>75.0%</b>	<b>3</b>
61-80%		0.0%	0
81-100%		0.0%	0
answered question			4
skipped question			1


## 8. How many years have you been in practice?

		Response Percent	Response Count
0-5 years		50.0%	2
6-15 years		50.0%	2
16-25 years		0.0%	0
26-30 years		0.0%	0
31+ years		0.0%	0
answered question			4
skipped question			1

## 9. Please rate the overall lecture: (5=Excellent, 1=Poor)

	5	4	3	2	1	Rating Average	Rating Count
Educational Content	100.0% (4)	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	4
Speaker Selection	100.0% (4)	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)	5.00	4
answered question							4
skipped question							1

### 10. Did any of the presentations contain pharmaceutical company or medical device manufacturer bias?

		Response Percent	Response Count
Yes		0.0%	0
No		100.0%	4

Comments(please be as specific as possible): 0

answered question	4
skipped question	1

### 11. List future CME topics that would be of value to you, and please be specific.

	Response Count
	2
answered question	2
skipped question	3

### 12. General Comments:

	Response Count
	2
answered question	2
skipped question	3

**Page 1, Q5. After participating in this activity, will you make any changes in your practice? (Please explain).**

1	No.	Jun 4, 2013 1:18 PM
2	Consider earlier referral for trials.	Jun 4, 2013 1:15 PM
3	Earlier referrals for transplant for myeloma patients.	Jun 4, 2013 1:11 PM

**Page 2, Q5. List future CME topics that would be of value to you, and please be specific.**

1	Any review topics, in particular after any major meeting	Jun 4, 2013 1:15 PM
2	Genito-urinary cancers.	Jun 4, 2013 1:13 PM

**Page 2, Q7. General Comments:**

1	Fantastic!	Jun 4, 2013 1:15 PM
2	Very good event! Informative + Enjoyable! Excellent!	Jun 4, 2013 1:13 PM